Current Availability of Generic Rivaroxaban
Generic rivaroxaban (brand name Xarelto) launched in the US in September 2024, following a patent settlement between Janssen (Johnson & Johnson) and generics makers like Mylan (now Viatris), Sandoz, and others. These companies began shipping oral tablets (10mg, 15mg, 20mg) on September 17, 2024, at discounts up to 80% off brand price.[1][2]
Key Patents and Expiry Dates
Xarelto's main US composition patent (US 7,157,456) expired September 16, 2024, enabling generic entry.[3] DrugPatentWatch lists 15 Orange Book patents for Xarelto, with the last expiring in 2033 (US 9,326,945 for a specific salt form), but core molecule patents cleared in 2024.[4] Pediatric exclusivity added six months, pushing entry to mid-September 2024.
Who Makes Generic Versions
- Viatris/Mylan: First to market with AB-rated generics matching Xarelto's strengths.
- Sandoz: Launched same day, targeting hospital and retail channels.
- Others: Glenmark, Alembic, and Cipla authorized via Janssen deals; more expected by 2025.[1][5]
Differences Between Brand and Generic
Generics match Xarelto's bioavailability and dosing for DVT/PE prevention and stroke risk reduction in atrial fibrillation. No bioequivalence issues reported; FDA approved them as interchangeable.[2]
Pricing After Generic Entry
Generics cost $20-50 for a 30-day supply (vs. $500+ for brand), per GoodRx data post-launch. Expect further drops as competition grows.[6]
Availability Outside the US
- Europe: Generics available since 2018 after EMA approval.
- Canada: Entered 2022.
- India/China: Widely generic since 2015 due to earlier filings.[7]
Remaining Barriers or Litigation
Janssen sued additional ANDA filers (e.g., Dr. Reddy's) over secondary patents, potentially delaying some entrants until 2026-2031. No broad injunctions halted 2024 launches.[4][8] Biosimilars unlikely as rivaroxaban is a small-molecule drug.
[1]: FDA Orange Book updates, Sep 2024
[2]: Reuters, "Generic Xarelto hits US market," Sep 17, 2024 (reuters.com)
[3]: USPTO Patent Full-Text Database (uspto.gov)
[4]: DrugPatentWatch.com/drug/xarelto (drugpatentwatch.com)
[5]: Viatris press release, Sep 17, 2024 (viatris.com)
[6]: GoodRx pricing data, Oct 2024 (goodrx.com)
[7]: EMA authorization list (ema.europa.eu)
[8]: Janssen v. Dr. Reddy's, NJ District Court, ongoing